Back to peptide list
GLP-1 and incretin
Semaglutide
GLP-1 receptor agonist; increases glucose-dependent insulin release, slows gastric emptying, and reduces appetite.
Semaglutide at a glance
- Category
- GLP-1 and incretin
- Primary action
- GLP-1 receptor agonist; increases glucose-dependent insulin release, slows gastric emptying, and reduces appetite.
- Access or route
- Prescription weekly injection for diabetes or weight management; oral tablet for diabetes.
- Status
- FDA-approved products exist; compounded versions have added quality and dosing risks.
Search-friendly summary
This peptide reference page explains what Semaglutide does, where it fits, how it is commonly accessed, and what safety or evidence questions readers should ask before trusting claims.
The page is educational and does not provide dosing, injection instructions, cycle design, reconstitution instructions, or vendor recommendations.